J2K Bio announced on the 9th that it has launched 'ACTS,' a cosmetic delivery platform based on different methods of active ingredient delivery technology. Since this platform technology can effectively deliver various raw materials to the dermis layer of the skin, it is expected to accelerate the development of new products with excellent efficacy.
Through the launch of this cosmetic delivery platform, J2K Bio has established its own value chain from raw material discovery to the development of high-functional products and efficacy verification. On the 6th, J2K Bio launched the library platform 'J2K METABIOME.ai' for discovering new raw materials. It is undergoing advancement through the application of artificial intelligence (AI) technology. In May of last year, the company established its own clinical center, 'HLK Clinical Center,' to set up an efficacy verification system for cosmetic raw materials and products.
ACTS is based on exosome technology, a biological delivery vehicle naturally produced by cells, with phospholipid bilayers as a main component. It enables precise delivery of raw materials to target points through different methods based on technologies suitable for various active ingredients, such as liposome technology and ferrocene-functional polymer-based reactive oxygen species-responsive drug systems.
J2K Bio is also working on internalizing active ingredients to further advance the ACTS platform. To this end, it is strengthening its in-house research and development capabilities while continuously collaborating with external research institutions. With the ability to verify the efficacy of ACTS-based products at its own clinical center, the competitiveness of its cosmetic business is expected to be further enhanced.
A J2K Bio official stated, "By utilizing the ACTS platform, we can continuously develop efficacy-verified products that effectively deliver raw materials to the human dermis layer," adding, "This platform will also have a positive impact on maximizing the company's market competitiveness and performance."
He continued, "Based on excellent in vivo absorption, the ACTS platform plans to expand into the field of health functional food raw materials in the future," and added, "Our goal is to further advance ACTS through collaboration with external institutions and ultimately develop it into a drug delivery platform."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
